Previous 10 | Next 10 |
- Robust 34% overall response rate and 9.1 months median duration of response across multiple NRG1+ tumor types - Zenocutuzumab observed to be well-tolerated - Oral presentation with additional patient data at ASCO on June 5, 2022, 9:45 -11:15 a.m. CT - Investor call to discus...
The following slide deck was published by Merus N.V. in conjunction with this event. For further details see: Merus N.V. (MRUS) Investor Presentation - Slideshow
Citi, which has a buy rating on Merus (NASDAQ:MRUS), is adding the biotech to its Catalyst Watch list ahead of presenting updated early-stage data on zenocutuzumab at the American Society of Clinical Oncology (OTC:ASCO) meeting in June. The firm lowered its price target by $1 to $37 (~134% up...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg...
Merus press release (NASDAQ:MRUS): Q1 GAAP EPS of -$0.43 beats by $0.22. Revenue of $11.66M (+39.6% Y/Y) beats by $2.29M. For further details see: Merus GAAP EPS of -$0.43 beats by $0.22, revenue of $11.66M beats by $2.29M
- Zenocutuzumab clinical abstract selected for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - Company to host investor call on Sunday, June 5 at 6:00 p.m. CT - Clinical data update of petosemtamab (Peto) and MCLA-129 planned for...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecifi...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecifi...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioNTech ( BNTX ) rose to fame with the tech that delivered the Pfizer ( PFE ) vaccine, but there’s more there than just the vaccine. BioCryst Pharmaceuticals ( BCRX ) is a commercial-stage biote...
– MCLA-129 promotes Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cell-Mediated Phagocytosis (ADCP) of non-small cell lung cancer (NSCLC) cells – MCLA-129 significantly inhibits growth of a patient-derived EGFR exon20 insertion (exon20...
News, Short Squeeze, Breakout and More Instantly...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...
2024-07-13 04:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...